RESISTENSI Mycobacterium Tuberculosis TERHADAP OBAT ANTI TUBERKULOSIS
| Autor: | A. Nikmawati, Windarwati Windarwati, Hardjoeno Hardjoeno |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Tuberculosis
biology business.industry Multi-drug-resistant tuberculosis Isoniazid Drug resistance medicine.disease biology.organism_classification Microbiology Mycobacterium tuberculosis Streptomycin medicine General Earth and Planetary Sciences business Rifampicin Ethambutol General Environmental Science medicine.drug |
| Zdroj: | INDONESIAN JOURNAL OF CLINICAL PATHOLOGY AND MEDICAL LABORATORY. 12:58-61 |
| ISSN: | 2477-4685 0854-4263 |
| DOI: | 10.24293/ijcpml.v12i2.843 |
| Popis: | Patients infected with resistant Mycobacterium tuberculosis strain will be very difficult to cure by standard treatment. To evaluatethe drug resistance of Mycobacterium tuberculosis. A Cross sectional study was performed from January until July 2005. Samples wereobtained from sputum of the suspect tuberculosis. All samples were cultured in Lowenstein-Jensen Media and followed by sensitivity testaccording to resistance ratio method. Of 236 samples, there were 30% positive cultures. The percentage of mono-resistance to Isoniazidwas 70%, to Rifampicin 64.3%, to Ethambutol 62.8% and Streptomycin 64.3%. The percentage of Multi Drug Resistant Tuberculosis(MDR-TB) was 20–40% and the percentage of poly-resistant (Ethambutol and Streptomycin) was 47.1%. The percentage of suspecttuberculosis with positive culture was 30%. There were also found high percentage of mono-resistant, poly-resistant and MDR-TB. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|